1-5 of 5
Alison T. Stopeck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515

Alison T. Stopeck, Joseph M. Unger, Lisa M. Rimsza, Michael LeBlanc, Brent Farnsworth, Maria Iannone, Martha J. Glenn, Richard I. Fisher, Thomas P. Miller
Journal: Blood
Blood (2012) 120 (6): 1210–1217.
https://doi.org/10.1182/blood-2012-04-423079
Published: 2012
Journal Articles

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

Alison T. Stopeck, MD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Brent Farnsworth, DO, Michael LeBlanc, Ph.D., Maria Iannone, MS, Richard I Fisher, MD, Thomas P. Miller, MD
Journal: Blood
Blood (2010) 116 (21): 591.
https://doi.org/10.1182/blood.V116.21.591.591
Published: 2010
Journal Articles

Decreased Bone Mineral Density among Patients with Hemophilia.

Gregory Gerstner, MD, Mary Lou Damiano, RN, MEd, Angela Tom, MS, FNP-C, Christina Worman, RN, BSN, Wendy Schultz, RN, BSN, Michael Recht, MD, PhD, Alison T. Stopeck, MD
Journal: Blood
Blood (2007) 110 (11): 1153.
https://doi.org/10.1182/blood.V110.11.1153.1153
Published: 2007
Journal Articles

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Clinical Trials & Observations
Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven E. Coutre, Richard M. Stone, Alison T. Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson
Journal: Blood
Blood (2007) 109 (12): 5136–5142.
https://doi.org/10.1182/blood-2006-11-056754
Published: 2007
Journal Articles

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

Clinical Trials & Observations
Francis J. Giles, Alison T. Stopeck, Lewis R. Silverman, Jeffrey E. Lancet, Maureen A. Cooper, Alison L. Hannah, Julie M. Cherrington, Anne-Marie O'Farrell, Helene A. Yuen, Sharianne G. Louie, Weiru Hong, Jorge E. Cortes, Srdan Verstovsek, Maher Albitar, Susan M. O'Brien, Hagop M. Kantarjian, Judith E. Karp
Journal: Blood
Blood (2003) 102 (3): 795–801.
https://doi.org/10.1182/blood-2002-10-3023
Published: 2003